Key facts
- This page summarizes Frederick W. Driscoll's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jul 2026, 21:10.
Frederick W. Driscoll - 07 Jul 2026 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)
- Reporting relationship
- Director
- Issuer ticker
- CLRB
- Reported as of
- 07 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2026, 21:10:28 UTC
- Prior SEC filing
- 18 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chad Kolean, attorney-in-fact for Frederick Driscoll
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Frederick W. Driscoll filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 08 Jul 2026.
Change
- Previous filing in this sequence was filed on 18 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001129890
Primary reporting owner
DRISCOLL FREDERICK W
- Relationship
- Director
- Address
- C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
- Signature
- /s/ Chad Kolean, attorney-in-fact for Frederick Driscoll
- Signature date
- 08 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLRB
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- $0.000000*
- Shares after
- 25,000
- Date
- 07 Jul 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 25,000
- Exercise price
- $2.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.